Otros
O transplante de células-tronco hematopoéticas como opção no tratamento de doenças não hematológicas
Fecha
2009-05-01Registro en:
Revista Brasileira de Hematologia e Hemoterapia, v. 31, n. SUPPL. 1, p. 68-74, 2009.
1516-8484
10.1590/S1516-84842009005000028
2-s2.0-69849104247
Autor
Universidade de São Paulo (USP)
Unidade de TCTH
Biomédico do IMC
Universidade Estadual Paulista (UNESP)
Institución
Resumen
In this report we discuss data and perspectives of hematopoietic stem cell transplantation in non-hematologic diseases. Aspects related to the conditioning regimen and its relationship with toxicity and mortality are also presented. Specific autoimmune diseases are discussed, in particular systemic lupus erythematosus, systemic sclerosis, multiple sclerosis and type 1 diabetes mellitus. The aim of the procedure in autoimmune diseases is immune reprogramming. Apparently this procedure has indications for diseases in which conventional treatments have failed when organ damage is not definitive, but likely to occur if transplantation is not performed. The most promising method appears to be autologous stem cell transplantation with non-myeloablative conditioning regimens to obtain survival that is estimated at more than 50% for all autoimmune diseases, with low toxicity and no mortality related to transplantation. The controversial results of solid tumor treatment and particularities of breast cancer are also presented. Hematopoietic stem cell transplantation is the apparent indication for solid tumors based on intensive treatment with myeloablative doses in order to induce the graft versus tumor effect. The myeloablative conditioning regimens are introduced with the purpose of reducing the toxicity and inducing immunosuppression but the data are insufficient and questionable requiring the introduction of new therapeutic strategies based on cellular and immune therapy.